Cargando…

β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer

Integrins belong to a large family of αβ heterodimeric transmembrane proteins first recognized as adhesion molecules that bind to dedicated elements of the extracellular matrix and also to other surrounding cells. As important sensors of the cell microenvironment, they regulate numerous signaling pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Blandin, Anne-Florence, Renner, Guillaume, Lehmann, Maxime, Lelong-Rebel, Isabelle, Martin, Sophie, Dontenwill, Monique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656837/
https://www.ncbi.nlm.nih.gov/pubmed/26635609
http://dx.doi.org/10.3389/fphar.2015.00279
_version_ 1782402287103115264
author Blandin, Anne-Florence
Renner, Guillaume
Lehmann, Maxime
Lelong-Rebel, Isabelle
Martin, Sophie
Dontenwill, Monique
author_facet Blandin, Anne-Florence
Renner, Guillaume
Lehmann, Maxime
Lelong-Rebel, Isabelle
Martin, Sophie
Dontenwill, Monique
author_sort Blandin, Anne-Florence
collection PubMed
description Integrins belong to a large family of αβ heterodimeric transmembrane proteins first recognized as adhesion molecules that bind to dedicated elements of the extracellular matrix and also to other surrounding cells. As important sensors of the cell microenvironment, they regulate numerous signaling pathways in response to structural variations of the extracellular matrix. Biochemical and biomechanical cues provided by this matrix and transmitted to cells via integrins are critically modified in tumoral settings. Integrins repertoire are subjected to expression level modifications, in tumor cells, and in surrounding cancer-associated cells, implicated in tumor initiation and progression as well. As critical players in numerous cancer hallmarks, defined by Hanahan and Weinberg (2011), integrins represent pertinent therapeutic targets. We will briefly summarize here our current knowledge about integrin implications in those different hallmarks focusing primarily on β1 integrins.
format Online
Article
Text
id pubmed-4656837
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-46568372015-12-03 β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer Blandin, Anne-Florence Renner, Guillaume Lehmann, Maxime Lelong-Rebel, Isabelle Martin, Sophie Dontenwill, Monique Front Pharmacol Pharmacology Integrins belong to a large family of αβ heterodimeric transmembrane proteins first recognized as adhesion molecules that bind to dedicated elements of the extracellular matrix and also to other surrounding cells. As important sensors of the cell microenvironment, they regulate numerous signaling pathways in response to structural variations of the extracellular matrix. Biochemical and biomechanical cues provided by this matrix and transmitted to cells via integrins are critically modified in tumoral settings. Integrins repertoire are subjected to expression level modifications, in tumor cells, and in surrounding cancer-associated cells, implicated in tumor initiation and progression as well. As critical players in numerous cancer hallmarks, defined by Hanahan and Weinberg (2011), integrins represent pertinent therapeutic targets. We will briefly summarize here our current knowledge about integrin implications in those different hallmarks focusing primarily on β1 integrins. Frontiers Media S.A. 2015-11-24 /pmc/articles/PMC4656837/ /pubmed/26635609 http://dx.doi.org/10.3389/fphar.2015.00279 Text en Copyright © 2015 Blandin, Renner, Lehmann, Lelong-Rebel, Martin and Dontenwill. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Blandin, Anne-Florence
Renner, Guillaume
Lehmann, Maxime
Lelong-Rebel, Isabelle
Martin, Sophie
Dontenwill, Monique
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
title β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
title_full β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
title_fullStr β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
title_full_unstemmed β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
title_short β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
title_sort β1 integrins as therapeutic targets to disrupt hallmarks of cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656837/
https://www.ncbi.nlm.nih.gov/pubmed/26635609
http://dx.doi.org/10.3389/fphar.2015.00279
work_keys_str_mv AT blandinanneflorence b1integrinsastherapeutictargetstodisrupthallmarksofcancer
AT rennerguillaume b1integrinsastherapeutictargetstodisrupthallmarksofcancer
AT lehmannmaxime b1integrinsastherapeutictargetstodisrupthallmarksofcancer
AT lelongrebelisabelle b1integrinsastherapeutictargetstodisrupthallmarksofcancer
AT martinsophie b1integrinsastherapeutictargetstodisrupthallmarksofcancer
AT dontenwillmonique b1integrinsastherapeutictargetstodisrupthallmarksofcancer